Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis

PHASE3CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

August 13, 2017

Primary Completion Date

June 30, 2021

Study Completion Date

March 30, 2022

Conditions
Acanthamoeba Keratitis
Interventions
DRUG

PHMB 0.08%

16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution

DRUG

Propamidine 0.1%

16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution

DRUG

placebo

16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution

DRUG

PHMB 0.02%

16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution

Trial Locations (6)

Unknown

San Raffaele Hospital, Milan

San Giovanni and Paolo Hospital, Venice

University Clinical Center Medical University of Silesia, Katowice

Moorfields Hospital, London

Manchester Royal Eye Hospital, Manchester

University Hospital Southampton, Southampton

All Listed Sponsors
lead

SIFI SpA

INDUSTRY

NCT03274895 - Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis | Biotech Hunter | Biotech Hunter